Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGN 241751

Drug Profile

AGN 241751

Alternative Names: AGN-241751

Latest Information Update: 27 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aptinyx
  • Developer Allergan
  • Class Antidepressants; Small molecules
  • Mechanism of Action NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 23 Oct 2019 Allergan completes a phase I/II trial for Major depressive disorder in USA (PO, Tablet) (NCT03726658)
  • 08 Nov 2018 Allergan initiates a phase I/II trial for Major depressive disorder in USA (NCT03726658)
  • 06 Nov 2018 Allergan plans a phase I/II trial for Major depressive disorder in November 2018 (NCT03726658)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top